Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea. Materials and Methods Thirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan- Meier analysis was used to describe survival. Results Of 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumors were located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity index was 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second- line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients. Conclusion Most patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.
Abstract
Purpose The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea. Materials and Methods Thirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan- Meier analysis was used to describe survival. Results Of 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumors were located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity index was 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second- line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients. Conclusion Most patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.
참고문헌 (23)
- Bang YJ, "Registry of gastric cancer treatment evaluation(REGATE) : I baseline disease characteristics", Asia Pac J Clin Oncol, 10, pp.38~52 (2014)
- Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136(5), pp.E359~E386 (2015)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Ter-Ovanesov M, "Registry of gastric cancer treatment evaluation(REGATE) : II treatment practice", Asia Pac J Clin Oncol, 9, pp.373~380 (2013)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Sobin LH, "TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer", Cancer, 80, pp.1803~1804 (1997)
- Hu B, "Gastric cancer : classification, histology and application of molecular pathology", J Gastrointest Oncol, 3, pp.251~261 (2012)
- 이준행, "Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach", Journal of Gastric Cancer, 14(2), pp.87~104 (2014), 대한위암학회[DOI]
- Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW) : a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
- Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
- Ford HE, "Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02) : an open-label, phase 3 randomised controlled trial", Lancet Oncol, 15, pp.78~86 (2014)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Kang JH, "Salvage chemotherapy for pretreated gastric cancer : a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone", J Clin Oncol, 30, pp.1513~1518 (2012)
- Thuss-Patience PC, "Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer : a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie(AIO)", Eur J Cancer, 47, pp.2306~2314 (2011)
- Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 358, pp.36~46 (2008)
- Ohtsu A, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study", J Clin Oncol, 29, pp.3968~3976 (2011)
- Wilson D, "Review of second-line chemotherapy for advanced gastric adenocarcinoma", Clin Oncol(R Coll Radiol), 17, pp.81~90 (2005)
- Iacovelli R, "Chemotherapy or targeted therapy as secondline treatment of advanced gastric cancer: a systematic review and meta-analysis of published studies", PLoS One, 9, pp.e108940~ (2014)
- Bang YJ, "Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer", J Clin Gastroenterol, 46, pp.637~648 (2012)
- Ajani JA, "Gastric cancer", J Natl Compr Canc Netw, 8, pp.378~409 (2010)
- "Gastric cancer (version 3.2015)" (2015)[URL]
- Elimova E, "Medical management of gastric cancer : a 2014 update", World J Gastroenterol, 20, pp.13637~13647 (2014)
- Hironaka S, "Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial", J Clin Oncol, 31, pp.4438~4444 (2013)